TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25583157

Group type: EXPERIMENTAL
Intervention: SBP-CV (systolic blood pressure coefficient of variation)
Number of subjects: 24593

Group type: EXPERIMENTAL
Intervention: Mean HR (heart rate)
Number of subjects: 24593

Group type: EXPERIMENTAL
Intervention: SBP-CV and Mean HR
Number of subjects: 24593

Group type: EXPERIMENTAL
Intervention: Cognitive dysfunction
Number of subjects: 24593

Group type: EXPERIMENTAL
Intervention: Important cognitive decline
Number of subjects: 24593

Group type: EXPERIMENTAL
Intervention: Cognitive deterioration
Number of subjects: 24593
Study: 23343372

Group type: COMPARATOR
Intervention: Cemented DLC all‐polyethylene cup (C)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Uncemented hydroxyapatite‐coated chrome‐cobalt Elektra screw cup (UC)
Number of subjects: 28
Study: 21403790

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Prazosin 1‐2 mg
Number of subjects: 40
Study: 18080763

Group type: EXPERIMENTAL
Intervention: IFN beta‐1a (44 microg, 12 MIU)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: IFN beta‐1a plus RBV (1,000‐1,200 mg/day)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: IFN beta‐1a
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: IFN beta‐1a plus RBV
Number of subjects: 26
Study: 16418617

Group type: EXPERIMENTAL
Intervention: Web-based education program
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 89
Study: 12891605

Group type: EXPERIMENTAL
Intervention: Direct stenting
Number of subjects: 79

Group type: COMPARATOR
Intervention: Predilation
Number of subjects: 79
Study: 11306831

Group type: EXPERIMENTAL
Intervention: Topical tacalcitol
Number of subjects: 9

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 9
Study: 9209899

Group type: EXPERIMENTAL
Intervention: Nafarelin 200 micrograms (Group A)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Nafarelin 400 micrograms (Group B)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Nafarelin 200 micrograms plus Norethisterone 1.2 mg (Group C)
Number of subjects: 49
Study: 8132186

Group type: EXPERIMENTAL
Intervention: Clozapine treatment for one year
Number of subjects: 30
Study: 3549802

Group type: EXPERIMENTAL
Intervention: 2% minoxidil
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 3% minoxidil
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo to 3% minoxidil crossover
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: All groups (2% minoxidil, 3% minoxidil, placebo to 3% crossover)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Topical minoxidil
Number of subjects: 149
Study: 29066586

Group type: EXPERIMENTAL
Intervention: Mechanical Insufflation-Exsufflation (MI-E)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional Chest Physiotherapy (CPT)
Number of subjects: 22
Study: 27440463

Group type: EXPERIMENTAL
Intervention: Adjusted dose of enoxaparin according to anti-factor Xa levels
Number of subjects: 144

Group type: COMPARATOR
Intervention: Fixed dose of 40 mg daily enoxaparin
Number of subjects: 144
Study: 23941101

Group type: EXPERIMENTAL
Intervention: Himalayan singing bowl (HSB)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Silence
Number of subjects: 51
Study: 24547662

Group type: EXPERIMENTAL
Intervention: Support-seeking process in older adults with CG
Number of subjects: 8
Study: 21142609

Group type: EXPERIMENTAL
Intervention: 300 μg/day transdermal testosterone patch (TTP)
Number of subjects: 967
Study: 18083543

Group type: EXPERIMENTAL
Intervention: Physical inactivity at baseline
Number of subjects: 1955

Group type: EXPERIMENTAL
Intervention: Physical inactivity at follow-up
Number of subjects: 1955
Study: 16531443

Group type: EXPERIMENTAL
Intervention: Response entropy before skin incision
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: State entropy before skin incision
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BIS before skin incision
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EEG variables (response entropy, state entropy) with increases in electrical stimulation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Difference between response entropy and state entropy with increases in electrical stimulation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EEG variables differentiating intensity of electrical stimulation
Number of subjects: 40
Study: 14723338

Group type: EXPERIMENTAL
Intervention: Blend of partially purified Yucca schidigera and Quillaja saponaria extracts (0.9 mg daily for 4 weeks)
Number of subjects: 0
Study: 11078048

Group type: EXPERIMENTAL
Intervention: Brief, computer-assisted dietary goal-setting intervention
Number of subjects: 320

Group type: COMPARATOR
Intervention: Telephone follow-up calls
Number of subjects: 320

Group type: COMPARATOR
Intervention: Community resources enhancement
Number of subjects: 320
Study: 8732309

Group type: EXPERIMENTAL
Intervention: 600-1200 mg of CX516
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 1349049

Group type: EXPERIMENTAL
Intervention: Fish oil (four 1 g Pikasol capsules containing 2.7 g n‐3 fatty acids per day)
Number of subjects: 533

Group type: COMPARATOR
Intervention: Olive oil (four 1 g capsules per day)
Number of subjects: 533

Group type: COMPARATOR
Intervention: No supplement
Number of subjects: 533
Study: 3945704

Group type: EXPERIMENTAL
Intervention: Extrafoveal condition (stimuli appeared laterally in one visual hemifield)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Foveal condition (stimuli appeared centrally on the fovea)
Number of subjects: 0
Study: 29084391

Group type: EXPERIMENTAL
Intervention: ROLLING (4 sets of 90‐s rolling massage)
Number of subjects: 26

Group type: COMPARATOR
Intervention: CONTROL (rest)
Number of subjects: 26
Study: 25864194

Group type: EXPERIMENTAL
Intervention: Single-dose trandolapril (1 mg, 2 mg, 4 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Multiple-dose trandolapril (2 mg/day for 6 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single-dose trandolapril
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single and multiple doses of trandolapril
Number of subjects: 12
Study: 24193173

Group type: EXPERIMENTAL
Intervention: Parker Flex-Tip tube (P)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Wire reinforced tube with posteriorly positioned tip bevel (WRP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Wire reinforced tube with anteriorly positioned tip bevel (WRA)
Number of subjects: 90
Study: 21597980

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 117
Study: 20090547

Group type: EXPERIMENTAL
Intervention: Intrepide trapidil‐eluting stent
Number of subjects: 40

Group type: COMPARATOR
Intervention: Taxus paclitaxel‐eluting stent
Number of subjects: 40
Study: 18333870

Group type: EXPERIMENTAL
Intervention: Maraviroc (doses ranged from 3 mg b.i.d. to 600 mg q.d.)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 88
Study: 17187540

Group type: EXPERIMENTAL
Intervention: Patient-directed electronic messages intervention
Number of subjects: 912

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 912
Study: 14575630

Group type: EXPERIMENTAL
Intervention: ITI Dental Implant System
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Southern Implant System
Number of subjects: 24
Study: 11221289

Group type: EXPERIMENTAL
Intervention: Barnidipine 10 mg
Number of subjects: 397

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Combination therapy with enalapril (up to 10 mg once daily)
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Barnidipine
Number of subjects: 397

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 397
Study: 8677286

Group type: EXPERIMENTAL
Intervention: Slow paced breathing (8 cpm)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fast paced breathing (30 cpm)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nonpaced breathing (spontaneous)
Number of subjects: 30
Study: 1557929

Group type: EXPERIMENTAL
Intervention: 1.0 micrograms antigen per dose, abbreviated schedule (days 0, 7, 21)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: 1.5 micrograms antigen per dose, abbreviated schedule (days 0, 7, 21)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: 2.0 micrograms antigen per dose, abbreviated schedule (days 0, 7, 21)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: 1.0 micrograms antigen per dose, conventional schedule (days 0, 28, 300)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: 1.5 micrograms antigen per dose, conventional schedule (days 0, 28, 300)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: 2.0 micrograms antigen per dose, conventional schedule (days 0, 28, 300)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Conventional schedule (days 0, 28, 300)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Abbreviated schedule (days 0, 7, 21)
Number of subjects: 379
Study: 4093346

Group type: EXPERIMENTAL
Intervention: Piperacillin (4 X 2 g for 48 h)
Number of subjects: 40
Study: 30599899

Group type: EXPERIMENTAL
Intervention: EGP (200 mg, twice a day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 28124589

Group type: EXPERIMENTAL
Intervention: ACC-001 + QS-21
Number of subjects: 213
Study: 26343476

Group type: EXPERIMENTAL
Intervention: Methadone treatment
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: HCV positive status
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Receiving food assistance
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Higher number of health problems
Number of subjects: 195
Study: 24261301

Group type: EXPERIMENTAL
Intervention: Thermopaste application at Shenque (CV 8) 0.5 hours before PPH
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Thermopaste application at Shenque (CV 8) 1.0 hours before PPH
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Thermopaste application at Shenque (CV 8) at the time of PPH (0 h)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no application)
Number of subjects: 100
Study: 21726445

Group type: EXPERIMENTAL
Intervention: Extended Brief Intervention (EBI) delivered by an Alcohol Specialist Nurse (ASN)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Extended Brief Intervention (EBI)
Number of subjects: 130
Study: 19695387

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg (followed by 200 mg q12h)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg (followed by 550 mg q12h)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg (study 2 only)
Number of subjects: 303
Study: 16544756

Group type: EXPERIMENTAL
Intervention: Homeopathic drug 'Avia-more'
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dimenhydrinate
Number of subjects: 0
Study: 14557430

Group type: EXPERIMENTAL
Intervention: Oral weekly ibandronate (20 mg)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Oral daily ibandronate (2.5 mg)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Both regimens (weekly and daily ibandronate)
Number of subjects: 235
Study: 10698393

Group type: EXPERIMENTAL
Intervention: A balanced mixed amino acid infusion (200 mL/hr) for 30 minutes immediately after the operation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 22
Study: 9088782

Group type: EXPERIMENTAL
Intervention: Subcutaneous nicotine injections (2 x 0.3 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Subcutaneous nicotine injections (2 x 0.6 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Subcutaneous nicotine (both doses)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Subcutaneous nicotine (0.6 mg)
Number of subjects: 36
Study: 1490435

Group type: EXPERIMENTAL
Intervention: Aztreonam, intramuscularly at a level of 50 to 80 mg/kg body weight per dose every 8 h for 7 days
Number of subjects: 57

Group type: COMPARATOR
Intervention: Chloramphenicol, orally in a dose of 50 to 70 mg/kg body weight every 6 h for 12 days
Number of subjects: 57
Study: 2987636

Group type: EXPERIMENTAL
Intervention: ACTH 4‐9 analog (40 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29943838

Group type: EXPERIMENTAL
Intervention: Antifungal agents (systemic and topical)
Number of subjects: 208
Study: 28831618

Group type: EXPERIMENTAL
Intervention: Behavioral HIV prevention intervention integrating in-person and mobile phone delivered HIV risk reduction counseling, and daily, personalized text or voice messages.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard of care (SOC) comparison condition
Number of subjects: 100
Study: 26296407

Group type: EXPERIMENTAL
Intervention: Good performance preceded by poor performance
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Borderline performance preceded by good performance
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Narrative comments
Number of subjects: 61
Study: 24565345

Group type: EXPERIMENTAL
Intervention: Informative group (IG) - guardian received an information leaflet about anesthesia
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (CG) - guardian received conventional information about anesthesia
Number of subjects: 72
Study: 21946964

Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction (MBSR)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 29
Study: 18838938

Group type: EXPERIMENTAL
Intervention: Racemic epinephrine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Levalbuterol
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Racemic albuterol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: All treatments (including saline)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Inhaled bronchodilator treatments
Number of subjects: 22
Study: 16122897

Group type: EXPERIMENTAL
Intervention: Educational intervention (BBN training program)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Balint group (control)
Number of subjects: 34
Study: 12618286

Group type: EXPERIMENTAL
Intervention: Nalbuphine 2.5 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Nalbuphine 2.5 mg + Naloxone 0.4 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Nalbuphine 5 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Nalbuphine 5 mg + Naloxone 0.4 mg
Number of subjects: 2
Study: 10556449

Group type: EXPERIMENTAL
Intervention: Warm gas
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cold gas
Number of subjects: 100
Study: 8712112

Group type: EXPERIMENTAL
Intervention: Primary Percutaneous Transluminal Coronary Angioplasty (PTCA)
Number of subjects: 395
Study: 1929022

Group type: EXPERIMENTAL
Intervention: Dietary advice aimed at selectively increasing potassium intake (group 1)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Customary diet unchanged (group 2)
Number of subjects: 54
Study: 6762195

Group type: EXPERIMENTAL
Intervention: chemo‐immunotherapy (BCG plus intradermal leukaemic blast cells)
Number of subjects: 264

Group type: COMPARATOR
Intervention: chemotherapy alone
Number of subjects: 264
Study: 31901284

Group type: EXPERIMENTAL
Intervention: Expander with differential opening (EDO)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Hyrax expander
Number of subjects: 46

Group type: COMPARATOR
Intervention: Both EDO and Hyrax expander
Number of subjects: 46
Study: 31159814

Group type: COMPARATOR
Intervention: 8-miRNA signature
Number of subjects: 120

Group type: COMPARATOR
Intervention: 16-miRNA signature
Number of subjects: 120
Study: 30003569

Group type: EXPERIMENTAL
Intervention: Pooling strategy using mixed blood samples from randomly selected subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple random sampling method
Number of subjects: 0
Study: 27224744

Group type: EXPERIMENTAL
Intervention: Cooling (COOL)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Warming (WARM)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Thermoneutral (NEUT)
Number of subjects: 21
Study: 24397441

Group type: EXPERIMENTAL
Intervention: Double balloon catheter (mechanical method group, 67 cases)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Dinoprostone 10mg controlled‐release vaginal insert (pharmacological method group, 59 cases)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Double balloon catheter
Number of subjects: 126

Group type: COMPARATOR
Intervention: Dinoprostone vaginal insert
Number of subjects: 126
Study: 22715371

Group type: EXPERIMENTAL
Intervention: Fibromyalgia patients
Number of subjects: 19

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 19
Study: 20237044

Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low-frequency electrical stimulation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-frequency electrical stimulation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All forms of acupuncture
Number of subjects: 24
Study: 17338763

Group type: EXPERIMENTAL
Intervention: Adjuvant anterior LA ablation during PVAI
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no adjuvant ablation)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Adjuvant anterior LA ablation during PVAI (for persistent/permanent AF)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no adjuvant ablation, for persistent/permanent AF)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Adjuvant anterior LA ablation during PVAI (for paroxysmal AF)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no adjuvant ablation, for paroxysmal AF)
Number of subjects: 200
Study: 15834273

Group type: EXPERIMENTAL
Intervention: Caffeine (median dose: 410 mg/day)
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Coffee (median intake: 725 ml/day)
Number of subjects: 1010
Study: 12031981

Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment for 10 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Withdrawal of insulin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nondiabetic control subjects
Number of subjects: 0
Study: 10051048

Group type: EXPERIMENTAL
Intervention: Tacrolimus (initial dose 0.03 to 0.4 mg/kg, median 0.052 mg/kg; maintenance dose 0.03 to 0.13 mg/kg/day)
Number of subjects: 14
Study: 7721409

Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg on each of 5 days preceding the study)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Candoxatrilat (200 mg IV)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Combination of enalapril and candoxatrilat
Number of subjects: 6

Group type: COMPARATOR
Intervention: Enalapril (5 mg)
Number of subjects: 6
Study: 1959863

Group type: EXPERIMENTAL
Intervention: 750 mg ursodeoxycholic acid alone (group A)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Combination of 500 mg ursodeoxycholic acid and 500 mg chenodeoxycholic acid (group B)
Number of subjects: 282
Study: 6786952

Group type: EXPERIMENTAL
Intervention: Insulin (30 IU added to each 1006 kcal of nutrient solution)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (nutrient solution of hypertonic glucose and amino acids, 44.7 +/- 9.0 kcal/kg/day)
Number of subjects: 16
Study: 31833718

Group type: EXPERIMENTAL
Intervention: 5-alpha reductase inhibitors (5-ARIs) for at least 12 months
Number of subjects: 423

Group type: COMPARATOR
Intervention: Untreated with 5-alpha reductase inhibitors (5-ARIs)
Number of subjects: 423
Study: 28040526

Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 87
Study: 25928772

Group type: EXPERIMENTAL
Intervention: Daily cell phone support intervention
Number of subjects: 37
Study: 24266968

Group type: EXPERIMENTAL
Intervention: rATG + rituximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rATG + bortezomib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rATG + rituximab + bortezomib
Number of subjects: 0

Group type: COMPARATOR
Intervention: rATG
Number of subjects: 0
Study: 21555748

Group type: EXPERIMENTAL
Intervention: Case-based training intervention for general practitioners over a 2-year period
Number of subjects: 255

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Patients treated by specialists (internal comparison group)
Number of subjects: 255
Study: 18762438

Group type: EXPERIMENTAL
Intervention: Prolonged-release oral oxycodone co-administered with naloxone (10 mg/day, 20 mg/day, 40 mg/day)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Prolonged-release oral naloxone (20 mg/day and 40 mg/day)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 17525906

Group type: EXPERIMENTAL
Intervention: 1-hour infusion of daunorubicin (DNR) at a dose of 36 mg/m²
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: 24-hour infusion of daunorubicin (DNR) at a dose of 36 mg/m²
Number of subjects: 178

Group type: COMPARATOR
Intervention: 1-hour infusion of daunorubicin (DNR)
Number of subjects: 178

Group type: COMPARATOR
Intervention: 24-hour infusion of daunorubicin (DNR)
Number of subjects: 178
Study: 12698257

Group type: EXPERIMENTAL
Intervention: Viscocanalostomy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin C
Number of subjects: 25
Study: 11071831

Group type: EXPERIMENTAL
Intervention: Moderate physical activity
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Vigorous physical activity
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Age group 65+
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Performance self-efficacy score
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Physical inactivity
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Aerobic fitness
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Physical activity levels
Number of subjects: 874
Study: 8929199

Group type: EXPERIMENTAL
Intervention: Tilted stripes (15 degrees)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Vertical stripes
Number of subjects: 45